Published in Bull Cancer on November 01, 2013
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol (2008) 0.89
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol (2005) 0.83
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2015) 0.83
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Invest New Drugs (2011) 0.83
Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.81
QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol (2009) 0.81
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs (2009) 0.80
Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol (2012) 0.79
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Curr Opin Oncol (2014) 0.79
Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr Urol Rep (2012) 0.78
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs (2010) 0.78
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol (2011) 0.78
Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78
[Locally advanced prostate cancer: definition, prognosis and treatment]. Bull Cancer (2007) 0.77
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin Genitourin Cancer (2012) 0.77
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients? Am J Clin Oncol (2012) 0.77
Delivery by shock waves of active principle embedded in gelatin-based capsules. Ultrason Sonochem (2007) 0.77
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Invest New Drugs (2013) 0.77
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2010) 0.77
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials. Onkologie (2013) 0.76
[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2011) 0.76
[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2012) 0.76
[EGF receptors in colorectal cancers]. Bull Cancer (2007) 0.76
New agents in metastatic prostate cancer. Eur J Cancer (2009) 0.76
[State of the art in nuclear imaging for the diagnosis of bone metastases]. Bull Cancer (2013) 0.75
A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy. J Clin Oncol (2009) 0.75
Toward a better dialogue between neuro-oncologists and phase I investigators. J Clin Oncol (2012) 0.75
[Specificity of bone metastases: pan-oncologic issues]. Bull Cancer (2013) 0.75
[Prognostic factors for patients with brain metastases]. Bull Cancer (2013) 0.75
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology (2015) 0.75
[Editorial]. Bull Cancer (2014) 0.75
Late recurrent testicular seminoma: histological evidence is required. Oncol Res Treat (2015) 0.75
[Bladder cancer. Editorial]. Bull Cancer (2010) 0.75
Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. Invest New Drugs (2009) 0.75
[EGFR/HER1: a target life]. Bull Cancer (2012) 0.75
[A point on a new year]. Bull Cancer (2016) 0.75
Wound healing delay after central venous access following DCF/VEGF-trap therapy. Invest New Drugs (2009) 0.75
[Neoadjuvant chemotherapy in non small cell lung cancer]. Bull Cancer (2006) 0.75
[Cell cycle, mitosis and therapeutic applications]. Bull Cancer (2011) 0.75
[Non oncologic applications of molecular targeted therapies]. Bull Cancer (2012) 0.75
[Otorhinolaryngology thematic issue. Presentation]. Bull Cancer (2014) 0.75
[Cannabis and cancer]. Bull Cancer (2006) 0.75
[Metronomic chemotherapy in 2011: update and perspectives]. Bull Cancer (2011) 0.75
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. Bull Cancer (2006) 0.75
[Nutrition and cancer: questions of balance]. Bull Cancer (2009) 0.75
[New hope in the treatment of advanced cancer of the prostate in 2012]. Bull Cancer (2012) 0.75
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. Clin Genitourin Cancer (2012) 0.75
[Brain metastases from breast cancer: usefulness and limits of prognostic scores]. Bull Cancer (2011) 0.75
[RB, guardian of prostatic tumor progression]. Bull Cancer (2011) 0.75
[MET: new target, new combinations]. Bull Cancer (2011) 0.75
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Invest New Drugs (2009) 0.75
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs (2017) 0.75
Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor. Onkologie (2010) 0.75